

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Fruquintinib for previously treated metastatic colorectal cancer ID6274

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Takeda (fruquintinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Bladder and Bowel UK • Bowel Cancer UK • Cancer 52 • Cancer Black Care • Cancer Equality • Colostomy UK • Crohn's and Colitis UK • Guts UK • Helen Rollason Cancer Charity • IA: Ileostomy and Internal Pouch Group • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Pelican Cancer Foundation • Sarcoma UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • Together Support Group <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Coloproctology of Great Britain and Ireland • Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland • British Geriatrics Society • British Institute of Radiology • British Oncology Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bayer (regorafenib) • Bristol Myers Squibb (ipilimumab, nivolumab) • Merck (cetuximab) • Pierre Fabre (encorafenib) • Servier Laboratories (trifluridine-tipiracil) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bowel Research UK • Cochrane UK • Cochrane Colorectal Group • Foundation for Liver research • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit

Provisional stakeholder list for the evaluation of fruquintinib for previously treated metastatic colorectal cancer ID6274. Issue date: October 2023

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Psychosocial Oncology Society • British Sarcoma Group • British Society of Gastroenterology • Cancer Research UK • Primary Care Society for Gastroenterology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Non-company consultees are invited to submit statements relevant to the group they are representing.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.